

Vitamin C in Cancer Treatment: Where Pharmacokinetics Speaks

Qi Chen*

Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas, 66160, USA

Editorial

One of the critical elements for a drug to be effective is the ability of the drug to reach its target organ in an effective concentration. The dynamic interactions among drug absorption, distribution, metabolism, and excretion determine the plasma concentration of a drug, and dictate the amount of free drug that reaches the target site, and therefore, influence the ultimate outcome the drug may provide. These basic principles in pharmacology state the importance of pharmacokinetics. In this article, we shall focus on one example that vividly demonstrates the importance of pharmacokinetics – the research on high dose vitamin C as treatment for cancer.

The claim for using large dose of vitamin C (ascorbate) to treat cancer was advocated in the 1970s by Linus Pauling, the two-time Nobel laureate, first based on his theory of “orthomolecular medicine”, and then supported by clinical data from Ewan Cameron, a Scottish surgeon. Cameron embellished the hypothesis that ascorbate inhibited the enzyme hyaluronidase, which otherwise destroyed collagen so that cancers could metastasize [1]. With only minimal *in vitro* data, Cameron treated terminally ill cancer patients with high doses of vitamin C - 10 grams per day intravenously for up to 10 days followed by 10 grams per day orally indefinitely. He had at least one spectacular success: a 45-year-old truck driver who had lymphoma had intravenous vitamin C without radiotherapy or chemotherapy. Within two weeks the patient became clinically well and able to return to work. He then stopped taking his vitamin C and relapsed, and again began treatment with vitamin C alone. The patient again responded well and was cured [2]. Of course, cancer cases occasionally undergo spontaneous remissions, but in this case the remissions had corresponded exactly with the vitamin C treatment, and it has not been known that a patient with this kind of cancer had undergone two spontaneous remissions. Cameron contacted Linus Pauling, who had his own interests in high-dose vitamin C. Pauling joined and championed Cameron's efforts. Together, they published a retrospective case series in 1976 in the Proceedings of the National Academy of Sciences [3], a paper that created a typhoon in the journal, among cancer scientists and physicians and with the general public. A follow-up paper in the same journal intensified the controversy 2 years later, with additional cases [4]. In both papers, the authors concluded that patients who had high dose vitamin C treatment benefited with improved quality and prolongation of life. Multiple scientific objections were raised: the lack of blinding inherent to a retrospective case-series design, the underlying susceptibility of the rural Scottish patient population to endogenous vitamin C deficiency, the lack of independent pathologic confirmation of diagnosis, and the possibility of a placebo effect [5-7].

Charles Moertel and colleagues at the Mayo Clinic designed two prospective double-blind placebo-controlled trials to attempt to restore scientific balance and civility. Neither, unfortunately, was restored. Enrolled patients in the first trial had prior chemotherapy [5], and in the second trial had none [6]. Both trials, using the same dose that Pauling and Cameron recommended, showed no effect of ascorbate. Sharp debates had been arisen between Pauling and the vitamin C critics. Unfortunately Pauling's objections were drowned by passionate opinions, and the medical community concluded that vitamin C

had no place in cancer treatment. Robert Wittes, in an editorial accompanying the second trial, wrote that ascorbate showed no utility in cancer treatment and should not be used. But he added a disclaimer: his conclusions could change if new evidence arose [8].

Pharmacokinetics of vitamin C had not been known at the time, and both sides on the debate neglected one simple thing: Cameron and Pauling used intravenous infusion of 10 grams Vitamin C per day for a week or more followed by daily oral doses, and the Mayo Clinic trials used the same 10 grams dose but only administered orally. Indeed, new evidence rose just from the different pharmacokinetic behaviors of intravenous versus oral vitamin C in large doses.

The pharmacokinetic study on oral vitamin C conducted by Mark Levine and colleagues at NIH was initially purposed to identify a dose-plasma concentration relationship for oral vitamin C ingestion, as a pre-requisite to study the dose-function relationship and to determine the optimal intake of this vitamin. Their results in healthy humans found that vitamin C concentrations in plasma and cells were carefully, or tightly, controlled by multiple mechanisms acting together: bioavailability, or intestinal absorption; tissue accumulation; renal reabsorption and excretion, and utilization rate as a function of homeostasis. Once oral intake of vitamin C exceeded 200 mg daily, the plasma concentration plateaued at 70~80 μM . Further increase in the dose did not provide obvious increase of concentration in plasma and in cells – the bioavailability drops, intracellular distribution saturated, and the renal excretion accelerated. However, when ascorbate was administered intravenously, tight control was bypassed, until renal excretion restored equilibrium – that could be hours depending on the dose [9-12].

With unequivocal data showing that intravenous ascorbate transiently bypassed tight control of oral doses, the NIH investigators surprisingly realized that pharmacokinetics had been overlooked in the earlier cancer studies [7]. At the doses used in these cancer trials, intravenous administration of ascorbate would produce concentrations around 5 mM which could never be achieved orally. Only high dose intravenous ascorbate was like a drug, producing concentrations that could be 70 to 100-fold higher than maximally tolerated oral doses [7,12]. Indeed, later researches found plasma ascorbate concentrations as high as 20-30 mM were safely achieved with large dose of intravenous ascorbate [13,14]. By contrast, oral intake did not provide plasma concentrations higher than 300 μM [12].

***Corresponding author:** Qi Chen, Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas, 66160, USA, Tel: (913) 588-3690; Fax: (913) 945- 6874; E-mail: sakshibhu@yahoo.co.in

Received August 16, 2012; **Accepted** August 17, 2012; **Published** August 22, 2012

Citation: Chen Q (2012) Vitamin C in Cancer Treatment: Where Pharmacokinetics Speaks. J Drug Metab Toxicol 3:e107. doi:10.4172/2157-7609.1000e107

Copyright: © 2012 Chen Q. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

If intravenous but not oral ascorbate was a drug, then the conclusion that ascorbate was not effective in cancer treatment was based on a false premise and deserved reexamination. Recent researches based on the new pharmacokinetic information have gained advances. High ascorbate concentrations achievable with parenteral administration have been proved cytotoxic to many cancer cells *in vitro* and inhibitory to xenografts *in vivo* [13,15]. Parenteral administrations raised ascorbate concentrations to millimolars both in plasma and in extracellular fluid of tissues [16]. These pharmacologic ascorbate concentrations produced both ascorbate radical and hydrogen peroxide in the extravascular space of tumor xenografts, which act as effector species and encountered pro-oxidant effects to tumor cells [13,16].

The discovery in pharmacokinetics re-opened the “closed” case of vitamin C in cancer treatment. Plasma concentration is critical. In this case, the anti-oxidant vitamin C turned out to exert pro-oxidant effect in the interstitial fluid in the tumor when raised to pharmacologic concentrations beyond the physiological tight control. Laboratories all over the world repeated and confirmed the anti-cancer activity of high dose parenteral ascorbate. Active researches are going on to identify down-stream molecular mechanisms. Several early phase clinical trials have been carried out [14,17] or are underway confirming the pharmacokinetics and safety of high dose intravenous ascorbate in cancer patients. Using proper design assisted by new information in mechanisms and pharmacokinetics, the controversies on vitamin C and cancer treatment might eventually be clarified with large clinical trials re-evaluating the efficacy. Advantage of using vitamin C in cancer treatment lies with its low toxicity which is especially valuable given the toxic side effects of most of the current standard chemotherapies.

References

1. Cameron E, Rotman D (1972) Ascorbic acid, cell proliferation, and cancer. *Lancet* 1: 542.
2. Cameron E, Campbell A, Jack T (1975) The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. *Chem Biol Interact* 11: 387-393.
3. Cameron E, Pauling L (1976) Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* 73: 3685-3689.
4. Cameron E, Pauling L (1978) Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* 75: 4538-4542.
5. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, et al. (1979) Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. *N Engl J Med* 301: 687-690.
6. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, et al. (1985) High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med* 312: 137-141.
7. Padayatty SJ, Levine M (2000) Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. *J Am Coll Nutr* 19: 423-425.
8. Wittes RE (1985) Vitamin C and cancer. *N Engl J Med* 312: 178-179.
9. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, et al. (1996) Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *Proc Natl Acad Sci U S A* 93: 3704-3709.
10. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR Jr, Wang Y, et al. (1997) Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. *Pharm Res* 14: 1133-1139.
11. Levine M, Wang Y, Padayatty SJ, Morrow J (2001) A new recommended dietary allowance of vitamin C for healthy young women. *Proc Natl Acad Sci U S A* 98: 9842-9846.
12. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, et al. (2004) Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern Med* 140: 533-537.
13. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al. (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. *Proc Natl Acad Sci U S A* 105: 11105-11109.
14. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, et al. (2008) Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. *Ann Oncol* 19: 1969-1974.
15. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, et al. (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci U S A* 102: 13604-13609.
16. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, et al. (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. *Proc Natl Acad Sci U S A* 104: 8749-8754.
17. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, et al. (2012) Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *PLoS One* 7: e29794.

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 200 Open Access Journals
- 15,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.editorialmanager.com/pharma>